DLH to Present at the Canaccord Genuity Conference on August 7

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ATLANTA, July 22, 2019 /PRNewswire/ — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare services and solutions to federal agencies, today announced that it will participate in the Canaccord Genuity 39th Annual Growth Conference on August 7, 2019 in Boston, where management will provide an overview of the Company’s operations and outlook. Institutional investors are welcome to participate in one-on-one meetings throughout the day, and a live audio webcast of the Company’s discussion will be available on the DLH website.

About DLH
DLH (NASDAQ:DLHC) serves federal government clients throughout the United States and abroad delivering technology enabled solutions in key health and human services programs. The Company’s core competencies and consulting services include assessment and compliance monitoring, program management, health IT systems integration, data analytics, medical logistics, and pharmacy solutions. DLH has over 1,600 employees serving numerous government agencies. For more information, visit the corporate website at www.dlhcorp.com

DLH Investor Relations
Contact: Chris Witty
Phone:  646-438-9385
Email:  cwitty@darrowir.com

 

View original content:http://www.prnewswire.com/news-releases/dlh-to-present-at-the-canaccord-genuity-conference-on-august-7-300887570.html

SOURCE DLH Holdings Corp.

Staff

Recent Posts

JLL Partners Announces Investment in Vascular Technology, Incorporated

Greg Groenke Appointed CEO; Lars Marcher Named Executive ChairmanNEW YORK--(BUSINESS WIRE)--JLL Partners (“JLL” or the…

1 hour ago

INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute

MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq:…

1 hour ago

Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis

The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program…

1 hour ago

EVA Pharma and Zhejiang Jinhua CONBA Bio-Pharm Sign Strategic Supply Agreement

Two Regional Powerhouses to Strengthen Cross-Border Collaboration for a More Resilient and Accessible Healthcare Supply…

1 hour ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65 Million in Contingent…

2 hours ago

Smartee Unveils ‘Live Update’ to Slash Treatment Planning Time from Days to Seconds

SHANGHAI, June 30, 2025 /PRNewswire/ -- In an era where real-time treatment agility defines competitive…

4 hours ago